Media ReleasesImmutep

View All Immutep News


Immutep to present AIPAC Overall Survival data at SABCS 2020


Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that interim Overall Survival (OS) resultsfrom its Phase IIb AIPAC study has been selected to be presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, which is being held virtually in December 2020 from Texas, USA. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.